92 results about "Tuberculosis diagnostics" patented technology

The present invention relates to MHC-peptide complexes and uses thereof in the diagnosis of, treatment of or vaccination against a disease in an individual. More specifically the invention discloses MHC complexes comprising Mycobacterium tuberculosis antigenic peptides and uses there of.

The invention discloses a kit for assisted diagnosis of tuberculosis, which comprises a specific antibody composition, wherein the specific antibody composition comprises the following five antibodies: (1) IFN-gamma antibody, (2) TNF-alpha antibody, (3) IL-2 antibody, (4) MIG antibody and (5) IP-10 antibody. The kit disclosed by the invention can distinguish a Mycobacterium tuberculosis infected person from a BCG vaccinee. Compared with the ELISPOT tuberculosis diagnosis method, the tuberculosis diagnosis kit based on multi-molecular marker detection has obviously enhanced sensitivity to active tuberculosis (from 72% to 89%), and the positive rate for normal healthy persons is obviously reduced (from 27% to 16%).

A method of diagnosing in a host infection by or exposure to a mycobacterium which expresses ESAT-6 comprising (i) contacting a population of T cells from the host with one or more peptides or analogues selected from the peptides represented by SEQ ID NO:1 to 11 and analogues thereof which can bind a T cell receptor which recognises any of the said peptides, and (ii) determining whether the T cells of said T cell population recognise the peptide(s) and/or analogue(s). The method may be performed in vivo. Peptides and a kit which enable the method to be carried out are provided.

The invention discloses a specific marker (Rv3119 recombinant protein) of mycobacterium tuberculosis and discloses an application of the Rv3119 recombinant protein in preparation a tuberculosis diagnostic reagent and a tuberculosis diagnostic kit. The Rv3119 specific antigen provided by the invention has high sensitivity in detecting phthisis, is a B cell target antigen with relatively strong activity, can be applied in preparation of rapid detection kit for the tuberculosis, and is safe and reliable.

The invention relates to a tuberculosis diagnostic composition and application of the tuberculosis diagnostic composition, in particular provides the tuberculosis diagnostic composition which consists of optional two or three of antigen ESAT-6 derived polypeptide, antigen CFP-10 derived polypeptide and antigen Rv3615c derived polypeptide. The invention also provides application of the tuberculosis diagnostic composition in a specific T cellular immune reaction caused by the detection of mycobacterium tuberculosis infection in vitro and application of the preparation of a tuberculosis diagnostic agent. Compared with the existing diagnostic technology, the diagnostic cost is reduced, the detection design and the operation process are simplified, and the detection sensitivity is obviously improved.

The invention provides a kit for diagnosing mycobacterium tuberculosis infection based on tuberculosis specificity IL-31 detection. The kit comprises an IL-31 capture antibody, an IL-31 detection antibody, tuberculosis specific antigen polypeptide, a diluent, a standard substance, a developing solution, a stop solution, a buffer solution, a solid carrier and a micro-plate sealer. The kit is used for detecting the IL-31 expression quantity in plasma, can be used for tuberculosis diagnosis, and is relatively high in sensitivity and accuracy, and fast to operate, so that the diagnosing efficiency of tuberculosis can be improved.

The invention provides an MS4A6A gene application, and relates to the preparation of products to distinguish latent tuberculosis infection and active tuberculosis. The preferred products include the products utilizing real-time quantitative PCR or gene chip detection to distinguish the latent tuberculosis infection and the active tuberculosis. According to the experimental results, the expression of the MS4A6A gene is obviously higher in the blood of tuberculosis patients than in healthy people or latent infection crowds, and therefore, the MS4A6A gene can serve as a special marking gene for the diagnosis of tuberculosis, so as to allow the tuberculosis diagnosis to be more accurate and quicker.

The present invention relates to a gamma-interferon sandwich ELISA detection method based on recombinant fusion antigen protein, further relates to a recombinant fusion antigen protein preparation method and a gamma-interferon monoclonal antibody preparation method, and belongs to the technical field of medical examination determination. According to the present invention, the recombinant fusion antigen protein is formed by linking secretory antigen protein MPB70, antigen protein CFP10 and antigen protein ESAT6 through peptide bonds, the gamma-interferon monoclonal antibody is prepared through immunization of animals, cell fusion, hybridoma cell screening, cloning and purification, and the recombinant fusion antigen protein and the gamma-interferon monoclonal antibody are adopted to establish a sandwich ELISA detection method; and the recombinant fusion antigen protein can rapidly stimulate a bovine blood sample to secret gamma-interferon, and the gamma-interferon monoclonal antibody can quickly and specifically identify bovine gamma-interferon, such that strong sensitivity and strong specificity are provided, and broad application prospects are provided in the field of buffalo tuberculosis diagnosis.

The invention relates to a method for capturing the phthisic Proteome in biological samples by supporting the stroma with the bead and separating the bead from the samples by the magnetic separator without the centrifuged samples. Then conduct the protein fingerprinting by the analysis of mass spectrography. The reagent kit tests the sensibility and the specificity of the normal person with the tuberculosis by Double Blind Test, which are all 100percent, among which the deviant SAA A can be used as blood serum in vitro for testing the normal person, minor tuberculosis patient, recrudescent tuberculosis patient, severe tuberculosis patient and tuberculosis patient after effective treatment. The elevated deviant SAA A shows poor treatment effectiveness, severe tuberculosis and the recrudescent tuberculosis, thus being a protein fingerprinting group for early warning of the early detection on tuberculosis worsening and prediction on tuberculosis recrudescence. The method provided in the invention can be used as the reagent kit to distinguish the protein fingerprinting or mass spectrum mapping between the normal person and the tuberculosis patient. The method is correct, convenient and fast.

The invention discloses a mycobacterium tuberculosis surface lipolysaccharide-antistatic nucleic acid aptamer and application thereof. The aptamer is a small molecular single-stranded deoxyribonucleic acid (ssDNA) which is specific to toxic mycobacterium tuberculosis surface lipolysaccharide ManLAM (Mannosylated Lipoarabinomannan) and has tuberculosis infection resisting and cellular immunity enhancing functions, and the nucleotide sequence of the ssDNA is shown as SEQIDNo.1. The small molecular ssDNA has a novel target spot and a novel structure which are different from those of the conventional anti-tuberculosis medicament, and has the immunologic suppression function of directly enclosing the ManLAM. The aptamer is easy to prepare and has low price; the obtained ssDNA aptamer is specifically combined on the surface of toxic mycobacterium tuberculosis; and the treatment targeting is further enhanced. The problems of increasing medicament tolerance and large side effect existing in the conventional treatment of tuberculosis are solved, and the aptamer can be taken as an effective novel anti-tuberculosis medicament or a tuberculosis diagnosis reagent.

The invention provides screening and application of active tuberculosis diagnosis molecules. In particular, the invention discloses high throughput screening of mycobacterium tuberculosis's important antigens and application thereof in active tuberculosis diagnosis. Based on a high throughput functional protein screening technology of GST fusion expression, 92 positive antigens recognizable by tuberculosis patients' serum are screened out, wherein 14 antigens present strongly positive reaction. Active tuberculosis serologic detection shows that the positive antigens have high sensitivity and specificity in detection of active tuberculosis. Specifically, TBGP1, TBGP2, TBGP3, TBGP4, TBGP5 and TBGP6 6 proteins form an antigen combination for tuberculosis serologic detection, and laboratory verification shows that the combination has high sensitivity and specificity in detection of mycobacterium tuberculosis, and has application value in tuberculosis diagnosis and monitoring.

The invention discloses microRNA biomarkers related to tuberculosis, and particularly provides a kit for tuberculosis detection. The biomarkers include microRNA (ribonucleic acid) 451a, microRNA542, microRNA125b, microRNA146a, microRNA29c, microRNA365, microRNA889, microRNA335 and microRNA342. Quantitative detection of the microRNA biomarkers can be achieved according to technologies such as nucleic acid chips, qPCR (quantitative polymerase chain reaction) or sequencing, so that the kit can be used for clinically auxiliary tuberculosis diagnosis or therapeutic outcome evaluation, sensitivity and specificity of tuberculosis diagnosis are improved, and the new basis is provided for clinical treatment evaluation.

The present invention provides a use of a CD157 gene for the preparation of products for distinguishing latent tuberculosis infection and active tuberculosis. The products for distinguishing latent tuberculosis infection and active tuberculosis preferably comprise products adopting real-time quantitative PCR or microarrays to determine and distinguish latent tuberculosis infection and active tuberculosis. Experiments prove that the expression level of the CD157 gene of the present invention in tuberculosis patient blood is significantly higher than that of healthy people as well as people with latent infection, so the CD157 gene can be used as a specific marker gene for diagnosis of tuberculosis, thus making tuberculosis diagnosis more accurate and faster.

Disclosed are methods and devices for analyzing aerosol particles in exhaled breath using diagnostic tools that enable rapid, low cost and autonomous point of care assays for several diseases including respiratory tract diseases. Disclosed are methods and devices for capturing exhaled breath aerosols in a packed bed column and analyzing exhaled captured breath aerosols for tuberculosis diagnosis.

The invention discloses an oligonucleotides aptamer of targeted mycobacterium tuberculosis Ag85B, a preparation method and application thereof. The oligonucleotides aptamer has nucleotide sequences shown as AP-1 to AP-13. The preparation method of the oligonucleotides aptamer comprises steps as follows: (1) constructing a random single-stranded DNA (ssDNA) library and preparing a primer; (2) preparing the random single-stranded DNA (ssDNA) library by PCR amplification; (3) carrying out SELEX screening; (4) detecting the appetency; (5) cloning and sequencing DNA. The oligonucleotides aptamer of targeted mycobacterium tuberculosis Ag85B is applied to detect the antigen level of the mycobacterium tuberculosis Ag85B in human serum, can replace antibodies, improves the sensitivity and the specificity of the tuberculosis antigen detection in specimens of body fluid (such as serum, hydrothorax, cerebrospinal fluid ascites and the like), thereby improving the accuracy rate of tuberculosis diagnosis.

The invention belongs to the technical field of tuberculosis diagnosis, and particularly discloses a recombinant protein for serodiagnosis of multimedicament-resistant tubercle bacilli. The recombinant protein is Rv1793 recombinant protein, and is obtained by the following steps of: inserting Rv1793 into the position between Pet28a EcoRI and HindIII endonuclease sites to form a recombinant plasmid, transforming the recombinant plasmid into E. coli BL21 to form recombinant E. coli, and expressing the protein. The sensitivity of the novel recombinant protein on the serodiagnosis of medicament resistance can reach 75 percent, and is far more than 53.3 percent of diagnosis rate of medicament resistance of a control CFP-10 recombinant protein. The Rv1793 recombinant protein becomes an effective biomarker applied to the serodiagnosis of medicament-resistant tuberculosis.

The invention belongs to the field of biological medicines, and relates to an application of a molecular marker CLEC2B in tuberculosis diagnosis. The invention provides an application of a reagent fordetecting the expression level of the molecular marker CLEC2B in preparation of a kit for diagnosing tuberculosis.

A tuberculosis diagnosis method based on deep-learning of the present invention comprises: a step of acquiring an image from a sputum smear slide made for training by using image capturing equipment;a learning step of learning a deep-learning model to be used to determine tuberculosis by using the acquired image; a verification step of verifying accuracy in the deep-learning model learned throughthe learning step; a step of determining negative or positive for tuberculosis by using a weighted value of the deep-learning model learned through the learning step and the verification step; and adisplaying step of providing, to a user, a test result made through the tuberculosis determination step by displaying the test result on a monitor.

In order to solve the problems including low tuberculosis diagnosis accuracy and heavy patient burdens caused by reasons such as medical resource lack and doctor experience lack, the invention provides an efficient method for sharing of tuberculosis information. The method is based on intelligent equipment and comprises the steps that (1) tuberculosis medical inspection results are collected; (2) an information network communication link is established; (3) a patient's basic medical record information and the tuberculosis medical inspection results are transmitted to a cloud side on the information network communication link; (4) connection between the information network communication link and the cloud side is maintained; and (5) the tuberculosis diagnosis results from the cloud side are received. According to the invention, the tuberculosis information is shared by a network; and the problems such as low efficiency and low accuracy of tuberculosis diagnosis in areas lacking software (such as doctor experience and doctor quantity) and/or hardware (such as lack of networked diagnosis and hospital management system) medical resources can be solved.

The invention discloses a protein chip and a kit for abortive tuberculosis diagnosis. The protein chip contains a specific antibody for 29 proteins. The protein chip can specifically separate an abortive tuberculosis patient from healthy people, nontuberculous pneumonia patients and the healed tuberculosis patients, has relatively high sensitivity and specificity, high flux and less consumption of specimens and is convenient in popularization and mass production in ordinary laboratories; and meanwhile, the application in the clinical diagnosis is favorable for more rapidly and accurately discovering the abortive tuberculosis patient and is expected to be used for screening the abortive tuberculosis and diagnosing the abortive tuberculosis, inspecting the healthy people, predicting and evaluating the curative effect of the tuberculosis treatment and the like, and provides strong technical support for controlling the situation of the tuberculosis.

The invention discloses an application of hsa-miR-378i as a marker molecule to preparation of a tuberculosis diagnosis reagent kit and a detection reagent kit for tuberculosis diagnosis. The hsa-miR-378i is from a plasma exosome, and the base sequence of the hsa-miR-378i is shown as SEQID NO:1. The detection reagent kit contains a detection reagent for specially detecting the marker molecule. Besides, the invention further discloses an application to preparation the tuberculosis diagnosis reagent kit through union of hsa-miR-378i and one or two of hsa-miR-148a-3p and hsa-miR-150-5p as the marker molecule. Experimental result indicates that hsa-miR-378i has high specificity, sensitivity and diagnosis effects on tuberculosis diagnosis. Therefore, the application has great application prospects and market prospects to the field of tuberculosis diagnosis.

The present invention relates to a novel bioactivity testing structure for single cell tracking using a gelling agent and a bioactivity testing system including the testing structure. The present invention also relates to bioactivity testing, drug susceptibility testing, antibiotic screening, and diagnostic methods using the testing structure. The bioactivity testing structure of the present invention enables very rapid and simple drug susceptibility testing of bacteria, particularly Mycobacterium tuberculosis, drug screening, and bacterial diagnosis. Particularly, the use of the testing structure enables DST and diagnosis of bacteria only by pretreatment without the need to concentrate human sputum samples irrespective of inoculum effect, ensuring rapid, accurate, and simple testing compared to conventional tuberculosis diagnosis or DST systems. In addition, the testing structure of the present invention simultaneously enables the diagnosis and drug susceptibility testing of tuberculosis. Therefore, the present invention provides an effective alternative to the prior art.

The invention relates to application of five antigen proteins in identification and diagnosis of active tuberculosis, provides a diagnostic reagent, and particularly relates to a novel tuberculosis diagnosis method which comprises the following steps of by taking the five antigen proteins P22352, Q9P121, P15151, Q13291 and Q8NDA2 as biomarkers, detecting the content of the five antigen proteins in urine, and taking the quantity value of the specific content as a diagnostic index, and indicating a negative result in the normal value range. And if the concentration of any three or more antigen proteins exceeds or is lower than the normal value range, the result is judged to be positive.